Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6228108 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL2201330 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL6224830 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL6252250 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL13356476 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL6253116 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL1339443 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL12280421 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL23886074 | 0.98 | HPGD (0.48) | HPGDRECQLEPHX1MAPTUSP2 | |
| Hydrochloric Acid SCHEMBL28504096 | 0.98 | HPGD (0.48) | HPGDRECQLEPHX1MAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025233174-A1 | BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-13 | — | — | WO | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12428403-B2 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-30 | — | — | US | disclosed |
| EP-4615849-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| CN-120202206-A | Cyclic benzimidazole derivatives as cGAS inhibitors | 勃林格殷格翰国际有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250188037-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2025-06-12 | — | — | US | disclosed |
| WO-2025096706-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-8063222-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063222-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7491827-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7378525-B2 | CCR8 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7329755-B2 | especially naphthalene sulfonamides, used for treating asthma | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1590327-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040209948-A1 | CCR8 Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004058709-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188037-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | SSTR4, SSTR3, SSTR1 | HPGD 3435/4885RECQL 1498/4885EPHX1 3940/4885 |
| US-12428403-B2 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | SSTR4, SSTR3, SSTR1 | HPGD 3472/4885RECQL 1209/4885EPHX1 3125/4885 |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | HPGD 2177/4885RECQL 2749/4885EPHX1 322/4885 |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | BCL6, BCL6B, BCL3 | HPGD 3604/4885RECQL 3895/4885EPHX1 3642/4885 |
| US-20040209948-A1 | CCR8 Inhibitors | CCR8, CCR1, CCR3 | HPGD 1350/4885RECQL 2422/4885EPHX1 928/4885 |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | HPGD 3604/4885RECQL 3895/4885EPHX1 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.